Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab for rituximab-dependent frequently relapsing idiopathic nephrotic syndrome in adults
2025-523306-33-00Phase 2Authorised
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Feb 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of obinutuzumab in Idiopathic nephrotic syndrome (INS), sponsored by Mario Negri Institute for Pharmacological Research. Primary endpoint: Relapse-free participants at 12 months. Planned start Feb 2026; status: authorised.
02
Drugs
obinutuzumab
03
Conditions
Idiopathic nephrotic syndrome (INS)
Beyond the preview
Go deeper on 2025-523306-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523306-33-00.